Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP16001 + DWC202213
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWP16001 + DWC202213 is a **combination of two investigational small molecule drugs**. DWP16001, also known as enavogliflozin, is a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor, developed primarily for the treatment of type 2 diabetes mellitus. Its mechanism is the inhibition of SGLT2 (SLC5A2), thereby reducing renal glucose reabsorption and increasing urinary glucose excretion, which lowers blood glucose levels. DWC202213 is also an experimental pharmaceutical; however, its precise structure, target, and mechanism of action are not publicly disclosed as of the most recent data. The combination is being investigated by Daewoong Pharmaceutical, with early-phase clinical trials comparing the safety and pharmacokinetics of the loose combination (DWP16001 + DWC202213) to a fixed-dose combination (DWJ1563)[3]. DWP16001 is marketed in some countries for type 2 diabetes, but the combination with DWC202213 appears to be in **early clinical development** (phase 1).
- Other names
- enavogliflozin/gemigliptinEnvlo/Zemiglo combination
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on DWP16001 + DWC202213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP16001 + DWC202213.